vs
INNODATA INC（INOD）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
PUMA BIOTECHNOLOGY, INC.的季度营收约是INNODATA INC的1.0倍（$75.5M vs $72.4M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs 22.3%），PUMA BIOTECHNOLOGY, INC.自由现金流更多（$14.4M vs $10.1M），过去两年INNODATA INC的营收复合增速更高（65.3% vs 31.3%）
Innodata Inc.（曾用名Innodata Isogen）是一家美国企业，专注于提供业务流程、技术及咨询服务，同时推出相关产品，助力客户完成数字信息的创建、管理、应用与分发，支持客户提升数字化运营效率。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
INOD vs PBYI — 直观对比
营收规模更大
PBYI
是对方的1.0倍
$72.4M
营收增速更快
PBYI
高出5.4%
22.3%
自由现金流更多
PBYI
多$4.3M
$10.1M
两年增速更快
INOD
近两年复合增速
31.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $72.4M | $75.5M |
| 净利润 | $8.8M | — |
| 毛利率 | 38.3% | 69.3% |
| 营业利润率 | 15.1% | 22.7% |
| 净利率 | 12.2% | — |
| 营收同比 | 22.3% | 27.7% |
| 净利润同比 | -14.2% | — |
| 每股收益（稀释后） | $0.26 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收INODPBYI
| Q4 25 | $72.4M | $75.5M | ||
| Q3 25 | $62.5M | $54.5M | ||
| Q2 25 | $58.4M | $52.4M | ||
| Q1 25 | $58.3M | $46.0M | ||
| Q4 24 | $59.2M | $59.1M | ||
| Q3 24 | $52.2M | $80.5M | ||
| Q2 24 | $32.6M | $47.1M | ||
| Q1 24 | $26.5M | $43.8M |
净利润INODPBYI
| Q4 25 | $8.8M | — | ||
| Q3 25 | $8.3M | $8.8M | ||
| Q2 25 | $7.2M | $5.9M | ||
| Q1 25 | $7.8M | $3.0M | ||
| Q4 24 | $10.3M | — | ||
| Q3 24 | $17.4M | $20.3M | ||
| Q2 24 | $-14.0K | $-4.5M | ||
| Q1 24 | $989.0K | $-4.8M |
毛利率INODPBYI
| Q4 25 | 38.3% | 69.3% | ||
| Q3 25 | 40.8% | 77.7% | ||
| Q2 25 | 39.4% | 76.5% | ||
| Q1 25 | 39.9% | 77.1% | ||
| Q4 24 | 45.2% | 76.4% | ||
| Q3 24 | 40.8% | 63.9% | ||
| Q2 24 | 28.7% | 77.4% | ||
| Q1 24 | 36.4% | 75.5% |
营业利润率INODPBYI
| Q4 25 | 15.1% | 22.7% | ||
| Q3 25 | 18.8% | 17.6% | ||
| Q2 25 | 15.3% | 12.7% | ||
| Q1 25 | 14.2% | 8.7% | ||
| Q4 24 | 19.0% | 22.6% | ||
| Q3 24 | 21.9% | 27.4% | ||
| Q2 24 | 1.0% | -4.6% | ||
| Q1 24 | 5.0% | -5.3% |
净利率INODPBYI
| Q4 25 | 12.2% | — | ||
| Q3 25 | 13.3% | 16.2% | ||
| Q2 25 | 12.4% | 11.2% | ||
| Q1 25 | 13.3% | 6.5% | ||
| Q4 24 | 17.4% | — | ||
| Q3 24 | 33.3% | 25.2% | ||
| Q2 24 | -0.0% | -9.6% | ||
| Q1 24 | 3.7% | -11.0% |
每股收益（稀释后）INODPBYI
| Q4 25 | $0.26 | $0.26 | ||
| Q3 25 | $0.24 | $0.17 | ||
| Q2 25 | $0.20 | $0.12 | ||
| Q1 25 | $0.22 | $0.06 | ||
| Q4 24 | $0.35 | $0.40 | ||
| Q3 24 | $0.51 | $0.41 | ||
| Q2 24 | $0.00 | $-0.09 | ||
| Q1 24 | $0.03 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.2M | $97.5M |
| 总债务越低越好 | — | $22.7M |
| 股东权益账面价值 | $107.1M | $130.3M |
| 总资产 | $168.6M | $216.3M |
| 负债/权益比越低杠杆越低 | — | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资INODPBYI
| Q4 25 | $82.2M | $97.5M | ||
| Q3 25 | $73.9M | $94.4M | ||
| Q2 25 | $59.8M | $96.0M | ||
| Q1 25 | $56.6M | $93.2M | ||
| Q4 24 | $46.9M | $101.0M | ||
| Q3 24 | $26.4M | $96.7M | ||
| Q2 24 | $16.5M | $96.8M | ||
| Q1 24 | $19.0M | $107.2M |
总债务INODPBYI
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
股东权益INODPBYI
| Q4 25 | $107.1M | $130.3M | ||
| Q3 25 | $97.3M | $115.3M | ||
| Q2 25 | $86.7M | $104.7M | ||
| Q1 25 | $75.5M | $97.1M | ||
| Q4 24 | $63.5M | $92.1M | ||
| Q3 24 | $47.7M | $71.1M | ||
| Q2 24 | $29.0M | $48.5M | ||
| Q1 24 | $27.6M | $51.0M |
总资产INODPBYI
| Q4 25 | $168.6M | $216.3M | ||
| Q3 25 | $152.9M | $202.9M | ||
| Q2 25 | $132.6M | $194.9M | ||
| Q1 25 | $125.2M | $196.2M | ||
| Q4 24 | $113.4M | $213.3M | ||
| Q3 24 | $88.2M | $220.7M | ||
| Q2 24 | $66.0M | $205.0M | ||
| Q1 24 | $63.6M | $214.1M |
负债/权益比INODPBYI
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $12.9M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | $10.1M | $14.4M |
| 自由现金流率自由现金流/营收 | 13.9% | 19.1% |
| 资本支出强度资本支出/营收 | 3.9% | 0.0% |
| 现金转化率经营现金流/净利润 | 1.46× | — |
| 过去12个月自由现金流最近4个季度 | $35.6M | $41.7M |
8季度趋势，按日历期对齐
经营现金流INODPBYI
| Q4 25 | $12.9M | $14.4M | ||
| Q3 25 | $18.8M | $9.7M | ||
| Q2 25 | $4.2M | $14.1M | ||
| Q1 25 | $10.9M | $3.6M | ||
| Q4 24 | $17.2M | $15.6M | ||
| Q3 24 | $11.4M | $11.0M | ||
| Q2 24 | $-454.0K | $1.0M | ||
| Q1 24 | $6.8M | $11.2M |
自由现金流INODPBYI
| Q4 25 | $10.1M | $14.4M | ||
| Q3 25 | $14.5M | $9.7M | ||
| Q2 25 | $2.5M | $14.1M | ||
| Q1 25 | $8.5M | $3.6M | ||
| Q4 24 | $15.0M | $15.6M | ||
| Q3 24 | $9.9M | $11.0M | ||
| Q2 24 | $-3.2M | $1.0M | ||
| Q1 24 | $5.4M | — |
自由现金流率INODPBYI
| Q4 25 | 13.9% | 19.1% | ||
| Q3 25 | 23.2% | 17.7% | ||
| Q2 25 | 4.3% | 26.8% | ||
| Q1 25 | 14.6% | 7.7% | ||
| Q4 24 | 25.3% | 26.4% | ||
| Q3 24 | 19.0% | 13.7% | ||
| Q2 24 | -9.8% | 2.1% | ||
| Q1 24 | 20.5% | — |
资本支出强度INODPBYI
| Q4 25 | 3.9% | 0.0% | ||
| Q3 25 | 6.8% | 0.0% | ||
| Q2 25 | 2.9% | 0.0% | ||
| Q1 25 | 4.0% | 0.1% | ||
| Q4 24 | 3.7% | 0.0% | ||
| Q3 24 | 2.8% | 0.0% | ||
| Q2 24 | 8.4% | 0.0% | ||
| Q1 24 | 5.1% | 0.0% |
现金转化率INODPBYI
| Q4 25 | 1.46× | — | ||
| Q3 25 | 2.25× | 1.10× | ||
| Q2 25 | 0.59× | 2.41× | ||
| Q1 25 | 1.40× | 1.21× | ||
| Q4 24 | 1.67× | — | ||
| Q3 24 | 0.65× | 0.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | 6.84× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
